MURFREESBORO, TN / ACCESS Newswire / April 15, 2025 / National Health Investors, Inc. (NYSE:NHI) announced details for the release of its results for the first quarter ended March 31, 2025. NHI plans ...

VANCOUVER, BC / ACCESS Newswire / April 15, 2025 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to announce that Company completed its previously ...

Sanofi today shared new progress from its mid- to late-stage respiratory pipeline, including preliminary phase 2 results for amlitelimab in adults with moderate-to-severe asthma.

GOTHENBURG, SE / ACCESS Newswire / April 15, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report January-March 2025.

CHEYENNE, WY / ACCESS Newswire / April 15, 2025 / Neuss, Germany: CS Diagnostics Corp. is pleased to announce that it has received a Letter of Intent from SAN ART CAPITAL SAS, a leading advisory and ...

Study Confirms Nasdepi® Dose Enabling Pivotal Biocomparability Study and Commercial Manufacturing RALEIGH, NORTH CAROLINA / ACCESS Newswire / April 15, 2025 / Belhaven Biopharma, a leader in ...

New survey insights from Brazilian healthcare leaders highlight financial, regulatory, and interoperability barriers limiting EHR expansion despite significant investments. MIAMI, FLORIDA / ACCESS ...

ATLANTA, GA / ACCESS Newswire / April 15, 2025 / May is Arthritis Awareness Month, and the Arthritis Foundation, the number one resource for arthritis resources and information, is introducing Green ...

A new, mid-size Contract Development Manufacturing Organisation (CDMO), Meribel Pharma Solutions has launched today with an extensive integrated network across Europe, led by a team of industry ...

Boehringer Ingelheim and Cue Biopharma, Inc. (Nasdaq: CUE) today announced a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma’s CUE-501 product ...

BRIDGEWATER, NJ / ACCESS Newswire / April 15, 2025 / Tharimmune, Inc. (NASDAQ:THAR), a clinical-stage biotechnology company advancing novel solutions in immunology and oncology, today announced the ...

Additional Evidence of PF614-MPAR Overdose Protection after Completion of Part 1 of Clinical Study ~ SAN DIEGO, CA / ACCESS Newswire / April 15, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ...